美罗培南
医学
药代动力学
粘菌素
药效学
舒巴坦钠
药理学
鲍曼不动杆菌
加药
人口
抗生素
重症监护医学
铜绿假单胞菌
生物
抗生素耐药性
微生物学
亚胺培南
细菌
环境卫生
遗传学
作者
Shixing Zhu,Jiayuan Zhang,Zhihua Lv,Peijuan Zhu,Charles Oo,Mingming Yu,Sherwin K. B. Sy
标识
DOI:10.1007/s40262-022-01161-y
摘要
BackgroundThe combination of polymyxins, meropenem, and sulbactam demonstrated efficacy against multi-drug-resistant bacillus Acinetobacter baumannii. These three antibiotics are commonly used against major blood, skin, lung, and heart muscle infections.ObjectiveThe objective of this study was to predict drug disposition and extrapolate the efficacy in these tissues using a physiologically based pharmacokinetic modeling approach that linked drug exposures to their target pharmacodynamic indices associated with antimicrobial activities against A. baumannii.MethodsAn adult physiologically based pharmacokinetic model was developed for meropenem, colistin, and sulbactam and scaled to pediatrics accounting for both renal and non-renal clearances. The model reliability was evaluated by comparing simulated plasma and tissue drug exposures to observed data. Target pharmacodynamic indices were used to evaluate whether pediatric and adult dosing regimens provided sufficient coverage.ResultsThe modeled plasma drug exposures in adults and pediatric patients were consistent with reported literature data. The mean fold errors for meropenem, colistin, and sulbactam were in the range of 0.710–1.37, 0.981–1.47, and 0.647–1.39, respectively. Simulated exposures in the blood, skin, lung, and heart were consistent with reported penetration rates. In a virtual pediatric population aged from 2 to < 18 years, the interpretive breakpoints were achieved in 85–90% of subjects for their targeted pharmacodynamic indices after administration of pediatric dosing regimens consisting of 30 mg/kg of meropenem, and 40 mg/kg of sulbactam three times daily as a 3-h or continuous infusion and 5 mg/kg/day of colistin base activity.ConclusionsThe physiologically based pharmacokinetic modeling supports pediatric dosing regimens of meropenem/colistin/sulbactam in a co-administration setting against infections in the blood, lung, skin, and heart tissues due to A. baumannii.
科研通智能强力驱动
Strongly Powered by AbleSci AI